“Reduced Venetoclax Dosage and Duration in AML: Favorable Response and Survival Rates”

https://pubmed.ncbi.nlm.nih.gov/38095287

The study found that reducing venetoclax dosage and duration in newly diagnosed AML patients treated with venetoclax and azacitidine resulted in favorable response rates and median survival, offering valuable insights for optimizing VEN-based regimens.